
Admetsys provides blood analysis and metabolic control for critical care and surgery.
admetsys.comCrawled Oct 14, 2026
Admetsys secures FDA Breakthrough Device designation for its automated glucose control system, which continuously monitors multiple blood analytes—including glucose—in real time without requiring patient blood loss. The technology targets a critical gap in diabetes care by integrating real-time diagnostics into glucose management. The system is designed for seamless, non-invasive blood analyte tracking, potentially improving treatment precision for patients.
Admetsys has obtained CE Mark approval for its PrecisionOne™ system, an automated solution for managing blood glucose levels and providing continuous diagnostics in critical care settings. The device integrates glycemic control with real-time monitoring to support clinical decision-making. Admetsys specializes in biomedical automation for intensive care applications.
AdmetSys develops an AI-powered artificial pancreas to automate blood sugar regulation for critically ill diabetes patients. The device adjusts glucose and insulin delivery in real time based on patient needs. It targets precise control to prevent dangerous fluctuations in blood sugar levels.
Admetsys, a startup focused on artificial pancreas technology for hospitals and surgical care, receives funding support from T1D Exchange. The investment aims to advance the development of its medical devices designed to automate insulin delivery for patients with diabetes.
Admetsys develops an **artificial pancreas system** to automate insulin dosing for hospitalized patients. The device integrates continuous glucose monitoring and insulin delivery to reduce manual calculations for nurses. The startup aims to improve diabetes management in clinical settings.